Posted by Michael Wonder on 03 May 2020
Pierre Fabre receives positive CHMP opinion for Braftovi (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer
1 May 2020 - If approved, the combination has the potential to be the first targeted regimen specifically for patients with BRAF V600E-mutant metastatic colorectal cancer.
Pierre Fabre today announced that the CHMP of the EMA adopted a positive opinion recommending approval of the indication of Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
This opinion is based on data from the Phase 3 BEACON CRC trial.
